News

Many ANCA-associated Vasculitis Patients with a Particular Antibody Have Bronchiectasis, Study Shows

Many ANCA-associated vasculitis patients who have a certain type of autoantibody develop the widened-airway condition known as bronchiectasis, a French study shows. The question of whether the respiratory tract is the place where ANCA-associated vasculitis develops remains to be seen, however, the researchers said. The hallmark of ANCA-associated vasculitis is…

GSK’s Nucala Approved by FDA as Add-on Therapy for EGPA Patients

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on to standard care for treating eosinophilic granulomatosis with polyangiitis (EGPA), previously called Churg-Strauss syndrome. “Patients suffering from EGPA too often face a frustrating journey from a delay in receiving a proper diagnosis to having…

Adding Azathioprine to Glucocorticoid Regimen Doesn’t Improve SNV Remission Rates, Study Finds

The addition of azathioprine, an immunosuppressant, to a glucocorticoid treatment regimen does not improve remission rates for patients with non-severe systemic necrotizing vasculitides (SNVs), a new study shows. The study, “Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without…

ANCA Vasculitis Treatment Research Advancing, Mayo Researchers Say

While the treatment of ANCA-associated vasculitis has taken strides away from highly toxic immunosuppressants to include an array of approaches based on biological drugs, there is plenty of room for treatment improvement. Research at the Mayo Clinic is focusing on approaches to prevent relapses of inflammatory disease activity. In a…